News

Arvinas (ARVN) delivered earnings and revenue surprises of +1,175.00% and +562.56%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

The biotech is clearly innovative, but sometimes that's not enough.

Heartflow scales AI diagnostics while Iovance drives personalized cancer therapies, each faces unique financial and operational risks in 2026.

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is one of the 10 Resilient Stocks Beating Market Slump. Iovance Biotherapeutics saw its share prices increase by 9.36 percent to close at $4.44 apiece, as investors positioned portfolios ahead of the end of the second quarter, supported by a recent regulatory approval that opened the door for its expansion into […]

Weigh the financial strength of a pharma leader against the rapid growth, and risks, of a biotech newcomer as both navigate industry headwinds.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the Best Penny Stocks That Could Skyrocket in 2026. On June 4, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) with a price target of $9. The analyst noted two key positive developments for AMTAGVI, which is Iovance’s lead therapy. ​Firstly, AMTAGVI […]

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is among the hidden penny stocks to invest in. As of June 10, Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) was trading near the low levels reported on June 3, before the stock appreciated following the Australian approval of Amtagvi. The stock has returned to its pre-approval levels. On June 4, TheFly reported that Iovance […]

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the top penny stocks to buy in investors’ stock portfolio. On June 1, research firm Citizens reiterated a Market Outperform rating on Iovanace Biotherapeutics (NASDAQ:IOVA) with a $5 price target. The research firm remains confident about the company’s outlook, impressed by the real-world presentation at ASCO that broadened […]

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the most shorted mid-cap and small-cap stocks to buy now. On May 8, Chardan reiterated Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) as a Buy but lowered its price target of the stock to $14 from $16. The price target cut is in response to Amtagvi’s launch guidance. The company delivered […]

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is one of the 9 Stocks Crushing the Market With Surging Returns. Iovance Biotherapeutics climbed by 15.57 percent on Thursday to end at $4.38 apiece after securing the conditional approval of Australia’s Therapeutic Goods Administration (TGA) for the treatment of melanoma through its therapy, Amtagvi. The approval marked Iovance Biotherapeutics Inc.’s (NASDAQ:IOVA) […]

Tread carefully, but certain factors make this speculative biotech play stand out.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the 10 Best Penny Stocks to Buy Before They Explode. On May 7, 2026, Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) reported Q1 EPS of (19c), versus the consensus estimate of (15c). Revenue totaled $71.43M, versus the consensus estimate of $75.66M. Interim President and Chief Executive Officer Frederick Vogt said the […]

Iovance Biotherapeutics reported past first-quarter 2026 results with revenue rising to US$71.43 million while net loss narrowed to US$79.05 million, alongside a proposal to lift authorized common shares to 650,000,000. Management highlighted AMTAGVI-driven growth and strengthened guidance supported by improving gross margins and encouraging early data in metastatic serous endometrial cancer, signaling operational and pipeline momentum. Now we’ll examine how this AMTAGVI-fueled revenue jump...

It could just as well drop by 50% -- or more -- over the next 12 months.